NASDAQ · KNTE
Kinnate Biopharma Inc.
$2.65-$0.01 (-0.38%)
Kinnate Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.12% below the high.
Loading market information…
NASDAQ · AADI · USD
Stock price, earnings
Quote as of Mar 18, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aadi Bioscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aadi Bioscience, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway. Its flagship drug candidate, FYARRO, is an investigational therapeutic composed of sirolimus conjugated with albumin. Aadi is actively evaluating FYARRO's efficacy in various malignancies that exhibit known mTOR pathway activation. This includes its application in 'tumor-agnostic' indications, where the focus is on specific genomic alterations that activate the mTOR pathway, irrespective of the tumor's origin. The company was established in 2007 and maintains its corporate headquarters in Pacific Palisades, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:35 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $5.35M-17.01% vs estimate |
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.65-$0.01 (-0.38%)
Kinnate Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.12% below the high.
$2.09-$0.01 (-0.48%)
HilleVax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.69% below the high.
$1.88$0.00 (0.0%)
Jounce Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.99% below the high.
$2.99-$0.19 (-5.87%)
Insight Molecular Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.83% below the high.
$0.35+$0.00 (+0.64%)
Asensus Surgical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.87% below the high.
$3.39+$0.02 (+0.59%)
Miromatrix Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.07% below the high.
$1.20-$0.08 (-5.88%)
Berkeley Lights, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.78% below the high.
$1.27$0.00 (0.0%)
IGM Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.36% below the high.
